p.108 抽出テキスト

with hypertrophic cardiomyopathy. Heart 2009;95:709–714. https://doi.org/10.1136/ hrt.2008.150656 522. Orgeron GM, James CA, Te Riele A, Tichnell C, Murray B, Bhonsale A, et al. Implantable cardioverter-defibrillator therapy in arrhythmogenic right ventricular dysplasia/cardiomyopathy: predictors of appropriate therapy, outcomes, and complications. J Am Heart Assoc 2017;6:e006242. https://doi.org/10.1161/JAHA.117.006242 523. Corrado D, Calkins H, Link MS, Leoni L, Favale S, Bevilacqua M, et al. Prophylactic implantable defibrillator in patients with arrhythmogenic right ventricular cardiomyopathy/dysplasia and no prior ventricular fibrillation or sustained ventricular tachycardia. Circulation 2010;122:1144–1152. https://doi.org/10.1161/ CIRCULATIONAHA.109.913871 524. Protonotarios A, Bariani R, Cappelletto C, Pavlou M, Garcia-Garcia A, Cipriani A, et al. Importance of genotype for risk stratification in arrhythmogenic right ventricular cardiomyopathy using the 2019 ARVC risk calculator. Eur Heart J 2022;43:3053–3067. https://doi.org/10.1093/eurheartj/ehac235 525. O’Mahony C, Jichi F, Pavlou M, Monserrat L, Anastasakis A, Rapezzi C, et al. Hypertrophic cardiomyopathy outcomes I. A novel clinical risk prediction model for sudden cardiac death in hypertrophic cardiomyopathy (HCM risk-SCD). Eur Heart J 2014;35:2010–2020. https://doi.org/10.1093/eurheartj/eht439 526. Jorda P, Bosman LP, Gasperetti A, Mazzanti A, Gourraud JB, Davies B, et al. Arrhythmic risk prediction in arrhythmogenic right ventricular cardiomyopathy: external validation of the arrhythmogenic right ventricular cardiomyopathy risk calculator. Eur Heart J 2022;43:3041–3052. https://doi.org/10.1093/eurheartj/ehac289 527. Masri A, Altibi AM, Erqou S, Zmaili MA, Saleh A, Al-Adham R, et al. Wearable cardioverter-defibrillator therapy for the prevention of sudden cardiac death: a systematic review and meta-analysis. JACC Clin Electrophysiol 2019;5:152–161. https:// doi.org/10.1016/j.jacep.2018.11.011 528. Connolly SJ, Gent M, Roberts RS, Dorian P, Roy D, Sheldon RS, et al. Canadian implantable defibrillator study (CIDS): a randomized trial of the implantable cardioverter defibrillator against amiodarone. Circulation 2000;101:1297–1302. https://doi.org/10. 1161/01.CIR.101.11.1297 529. Antiarrhythmics versus Implantable Defibrillators Investigators. A comparison of antiarrhythmic-drug therapy with implantable defibrillators in patients resuscitated from near-fatal ventricular arrhythmias. N Engl J Med 1997;337:1576–1583. https:// doi.org/10.1056/NEJM199711273372202 530. Kuck KH, Cappato R, Siebels J, Ruppel R. Randomized comparison of antiarrhythmic drug therapy with implantable defibrillators in patients resuscitated from cardiac arrest: the Cardiac Arrest Study Hamburg (CASH). Circulation 2000;102:748–754. https://doi.org/10.1161/01.CIR.102.7.748 531. Connolly SJ, Hallstrom AP, Cappato R, Schron EB, Kuck KH, Zipes DP, et al. Meta-analysis of the implantable cardioverter defibrillator secondary prevention trials. Eur Heart J 2000;21:2071–2078. https://doi.org/10.1053/euhj.2000.2476 532. Elliott PM, Sharma S, Varnava A, Poloniecki J, Rowland E, McKenna WJ. Survival after cardiac arrest or sustained ventricular tachycardia in patients with hypertrophic cardiomyopathy. J Am Coll Cardiol 1999;33:1596–1601. https://doi.org/10.1016/S0735- 1097(99)00056-X 533. Cleland JG, Daubert JC, Erdmann E, Freemantle N, Gras D, Kappenberger L, et al. The effect of cardiac resynchronization on morbidity and mortality in heart failure. N Engl J Med 2005;352:1539–1549. https://doi.org/10.1056/NEJMoa050496 534. Cecchi F, Maron BJ, Epstein SE. Long-term outcome of patients with hypertrophic cardiomyopathy successfully resuscitated after cardiac arrest. J Am Coll Cardiol 1989;13: 1283–1288. https://doi.org/10.1016/0735-1097(89)90302-1 535. Miron A, Lafreniere-Roula M, Steve Fan CP, Armstrong KR, Dragulescu A, Papaz T, et al. A validated model for sudden cardiac death risk prediction in pediatric hypertrophic cardiomyopathy. Circulation 2020;142:217–229. https://doi.org/10.1161/ CIRCULATIONAHA.120.047235 536. Aquaro GD, De Luca A, Cappelletto C, Raimondi F, Bianco F, Botto N, et al. Comparison of different prediction models for the indication of implanted cardioverter defibrillator in patients with arrhythmogenic right ventricular cardiomyopathy. ESC Heart Fail 2020;7:4080–4088. https://doi.org/10.1002/ehf2.13019 537. Baudinaud P, Laredo M, Badenco N, Rouanet S, Waintraub X, Duthoit G, et al. External validation of a risk prediction model for ventricular arrhythmias in arrhythmogenic right ventricular cardiomyopathy. Can J Cardiol 2021;37:1263–1266. https://doi. org/10.1016/j.cjca.2021.02.018 538. Bosman LP, Nielsen Gerlach CL, Cadrin-Tourigny J, Orgeron G, Tichnell C, Murray B, et al. Comparing clinical performance of current implantable cardioverter-defibrillator implantation recommendations in arrhythmogenic right ventricular cardiomyopathy. Europace 2022;24:296–305. https://doi.org/10.1093/europace/euab162 539. Cadrin-Tourigny J, Bosman LP, Nozza A, Wang W, Tadros R, Bhonsale A, et al. A new prediction model for ventricular arrhythmias in arrhythmogenic right ventricular cardiomyopathy. Eur Heart J 2022;43:e1–e9. https://doi.org/10.1093/eurheartj/ehac180 540. Kayvanpour E, Sammani A, Sedaghat-Hamedani F, Lehmann DH, Broezel A, Koelemenoglu J, et al. A novel risk model for predicting potentially life-threatening arrhythmias in non-ischemic dilated cardiomyopathy (DCM-SVA risk). Int J Cardiol 2021; 339:75–82. https://doi.org/10.1016/j.ijcard.2021.07.002 541. Wahbi K, Ben Yaou R, Gandjbakhch E, Anselme F, Gossios T, Lakdawala NK, et al. Development and validation of a new risk prediction score for life-threatening ventricular tachyarrhythmias in laminopathies. Circulation 2019;140:293–302. https://doi. org/10.1161/CIRCULATIONAHA.118.039410 542. Verstraelen TE, van Lint FHM, Bosman LP, de Brouwer R, Proost VM, Abeln BGS, et al. Prediction of ventricular arrhythmia in phospholamban p.Arg14del mutation carriersreaching the frontiers of individual risk prediction. Eur Heart J 2021;42:2842–2850. https://doi.org/10.1093/eurheartj/ehab294 543. Knops RE, Olde Nordkamp LRA, Delnoy PHM, Boersma LVA, Kuschyk J, El-Chami MF, et al. Subcutaneous or transvenous defibrillator therapy. N Engl J Med 2020;383: 526–536. https://doi.org/10.1056/NEJMoa1915932 544. Cardim N, Brito D, Rocha Lopes L, Freitas A, Araujo C, Belo A, et al. The Portuguese registry of hypertrophic cardiomyopathy: overall results. Rev Port Cardiol (Engl Ed) 2018;37:1–10. https://doi.org/10.1016/j.repc.2017.08.005 545. McKenna WJ, Judge DP. Epidemiology of the inherited cardiomyopathies. Nat Rev Cardiol 2021;18:22–36. https://doi.org/10.1038/s41569-020-0428-2 546. Pelliccia F, Limongelli G, Autore C, Gimeno-Blanes JR, Basso C, Elliott P. Sex-related differences in cardiomyopathies. Int J Cardiol 2019;286:239–243. https://doi.org/10. 1016/j.ijcard.2018.10.091 547. Perez-Sanchez I, Romero-Puche AJ, Garcia-Molina Saez E, Sabater-Molina M, Lopez-Ayala JM, Munoz-Esparza C, et al. Factors influencing the phenotypic expression of hypertrophic cardiomyopathy in genetic carriers. Rev Esp Cardiol (Engl Ed) 2018;71: 146–154. https://doi.org/10.1016/j.rec.2017.06.002 548. Argiro A, Ho C, Day SM, van der Velden J, Cerbai E, Saberi S, et al. Sex-related differences in genetic cardiomyopathies. J Am Heart Assoc 2022;11:e024947. https://doi.org/ 10.1161/JAHA.121.024947 549. Shah RA, Asatryan B, Sharaf Dabbagh G, Aung N, Khanji MY, Lopes LR, et al. Genotype-first approach I. Frequency, penetrance, and variable expressivity of dilated cardiomyopathy-associated putative pathogenic gene variants in UK Biobank participants. Circulation 2022;146:110–124. https://doi.org/10.1161/CIRCULATIONAHA. 121.058143 550. de Marvao A, McGurk KA, Zheng SL, Thanaj M, Bai W, Duan J, et al. Phenotypic expression and outcomes in individuals with rare genetic variants of hypertrophic cardiomyopathy. J Am Coll Cardiol 2021;78:1097–1110. https://doi.org/10.1016/j.jacc.2021. 07.017 551. McGurk KA, Zheng SL, Henry A, Josephs K, Edwards M, de Marvao A, et al. Correspondence on “ACMG SF v3.0 list for reporting of secondary findings in clinical exome and genome sequencing: a policy statement of the American College of Medical Genetics and Genomics (ACMG)” by Miller et al. Genet Med 2022;24:744–746. https:// doi.org/10.1016/j.gim.2021.10.020 552. Maron BJ, Casey SA, Olivotto I, Sherrid MV, Semsarian C, Autore C, et al. Clinical course and quality of life in high-risk patients with hypertrophic cardiomyopathy and implantable cardioverter-defibrillators. Circ Arrhythm Electrophysiol 2018;11: e005820. https://doi.org/10.1161/CIRCEP.117.005820 553. Ingles J, Sarina T, Kasparian N, Semsarian C. Psychological wellbeing and posttraumatic stress associated with implantable cardioverter defibrillator therapy in young adults with genetic heart disease. Int J Cardiol 2013;168:3779–3784. https://doi.org/10. 1016/j.ijcard.2013.06.006 554. James CA, Tichnell C, Murray B, Daly A, Sears SF, Calkins H. General and diseasespecific psychosocial adjustment in patients with arrhythmogenic right ventricular dysplasia/cardiomyopathy with implantable cardioverter defibrillators: a large cohort study. Circ Cardiovasc Genet 2012;5:18–24. https://doi.org/10.1161/CIRCGENETICS. 111.960898 555. Rhodes AC, Murray B, Tichnell C, James CA, Calkins H, Sears SF. Quality of life metrics in arrhythmogenic right ventricular cardiomyopathy patients: the impact of age, shock and sex. Int J Cardiol 2017;248:216–220. https://doi.org/10.1016/j.ijcard.2017.08.026 556. Sweeting J, Ball K, McGaughran J, Atherton J, Semsarian C, Ingles J. Impact of the implantable cardioverter defibrillator on confidence to undertake physical activity in inherited heart disease: a cross-sectional study. Eur J Cardiovasc Nurs 2017;16:742–752. https://doi.org/10.1177/1474515117715760 557. Sears SF Jr, Conti JB. Quality of life and psychological functioning of icd patients. Heart 2002;87:488–493. https://doi.org/10.1136/heart.87.5.488 558. Ingles J, Spinks C, Yeates L, McGeechan K, Kasparian N, Semsarian C. Posttraumatic stress and prolonged grief after the sudden cardiac death of a young relative. JAMA Intern Med 2016;176:402–405. https://doi.org/10.1001/jamainternmed.2015.7808 559. Stiles MK, Wilde AAM, Abrams DJ, Ackerman MJ, Albert CM, Behr ER, et al. 2020 APHRS/HRS expert consensus statement on the investigation of decedents with sudden unexplained death and patients with sudden cardiac arrest, and of their families. Heart Rhythm 2021;18:e1–e50. https://doi.org/10.1016/j.hrthm.2020.10.010 560. van den Heuvel LM, Sarina T, Sweeting J, Yeates L, Bates K, Spinks C, et al. A prospective longitudinal study of health-related quality of life and psychological wellbeing after an implantable cardioverter-defibrillator in patients with genetic heart diseases. Heart Rhythm O2 2022;3:143–151. https://doi.org/10.1016/j.hroo.2022.02.003 561. Passman R, Subacius H, Ruo B, Schaechter A, Howard A, Sears SF, et al. Implantable cardioverter defibrillators and quality of life: results from the defibrillators in Downloaded from academic.oup.com/eurheartj/article/44/37/3503/7246608 by guest on 07 October 2026